Last updated on April 16, 2014 at 17:34 EDT

CytoCare Wins Cancer Robotics Public Tender Award At Oxaliplatin Inventor-Nagoya City University Hospital

November 2, 2011

BOZEN, SUD-TIROL, Italy, November 2, 2011 /PRNewswire/ –

Health Robotics announced that CytoCare and Japan-based Tosho Inc.
recently won a public tender purchasing process, sponsored by the
Oxaliplatin Fund, at prestigious Nagoya City University Hospital’s Cancer
Center http://www.med.nagoya-cu.ac.jp/w3med/en/index.html

Nagoya City University Hospital is one of the most influential Oncology
hospitals in Asia-Pacific, and the birthplace (1976) of Oxaliplatin, a
platinum-based chemotherapy drug in the same family as cisplatin and
carboplatin that is typically administered in combination with fluorouracil
and leucovorin in a well-known protocol known as FOLFOX for the treatment of
colorectal cancer. The Oxaliplatin Fund [a not-for-profit unit that collects
Oxaliplatin's royalties from distributor Sanofi-Aventis] financially
sponsored this open and public tender award for the benefit of Nagoya City
University Hospital, which will now represent Tosho’s third CytoCare
installation in Japan, after Kameda Hospital and National Cancer Center

“All of us at Health Robotics are very proud of Tosho’s commitment to
our partnership in Japan. This contract dispels the myths spread by both
Japanese (Panasonic) and Canadian (IHS-RIVA) companies publicly stating in
2009-2010 that they were entering the Japanese I.V. Robotics market. The
fact of the matter is that none of our competitors even dared to respond to
Nagoya City University Hospital/Oxaliplatin Fund public tender for an I.V.
Compounding Cancer Therapy Robot and accept the challenge to compete with
CytoCare’s proven results, as judged by the independence and Oncology
expertise of Oxaliplatin’s inventors,” stated Gaspar DeViedma, Health
Robotics’ Executive Vice President.

CytoCare was the first and still only Robot proven to work anywhere in
the world for the safe and sterile preparation of Chemotherapy. With 65+
installations currently under contract in 17 countries, CytoCare has long
proven its unmatched flexibility to adapt to diverse pharmacy workflows and
disparate I.V. consumables globally. While several companies[1] attempted
the development of Chemo Robots as far back as 22 years ago[2], Cytocare is
still the only Robot that has been able to break the entry-barrier into the
Chemotherapy field and deliver “live” patient doses.

Additionally, Health Robotics announced today that it will showcase its
next-generation i.v.STATION ONCO Robot, and also a revolutionary
Mechatronics[3] solution for the reconstitution of Monoclonal Antibody
Therapy (mAbs) at the upcoming American Society of Health System Pharmacists
(ASHP) 46th Midyear Clinical Meeting & Exhibition, to be held at New
Orleans, Louisiana on 4-8 December 2011 (Booth 619). Health Robotics’
ground-breaking mAbs robotics solution will be announced to the world press
next week, on 9 November 2011.

About Health Robotics:

Founded in 2006, Health Robotics is the undisputed global leading
supplier of life-critical intravenous medication robots, winning 100% of all
worldwide I.V. Robot’s publicly announced purchases over the past 21 months,
and providing well over 200 hospital installations under contract in 6
continents with robotics-based technology and software automation solutions.
Health Robotics’ world-leading solutions CytoCare(R) and i.v.STATION(R) ONCO
[hazardous IVs], i.v.STATION(R) [non-hazardous IVs], i.v.SOFT(R) [workflow
engine for manual compounding], MEDarchiver(R) [life-critical clinical
information system], and TPNstation(TM) [totally-automated parenteral
nutrition] have and will greatly contribute to ease hospitals’ growing
pressures to improve patient safety, increase throughput and contain costs.
Through the effective and efficient production of sterile, accurate,
tamper-evident and ready-to-administer IVs, Health Robotics’ products help
hospitals eliminate life-threatening drug and diluent exchange errors,
decrease other medical mistakes and sterility risks, work more efficiently,
reduce waste and controlled substances’ diversion, and diminish the gap
between rising patient volume/acuity and scarce medical, nursing, and
pharmacy staff. For more information, please visit:


About Tosho:

TOSHO Inc., was founded in Tokyo in 1971, and currently has over 500
employees, more than 18,000 customers, and annual revenues in excess of US
$300 million. TOSHO was the world’s pioneer in the development of Pharmacy
Automation solutions for dispensing oral medications, powder, vials, and
ampoules and created an industry that now exceeds several billion dollars.
TOSHO’s solutions have become the gold standard for medication packaging and
dispensing solutions [tablets, vials, and powders] in hospital and retail
pharmacies in Japan, Asia and Europe. Tosho Inc. is a minority shareholder
in Health Robotics and its CEO is a member of Health Robotics’ Board of
Directors. For more information, please visit http://www.tosho.cc/en

1. Companies that announced Oncology Robots: IHS/RIVA, For Health, MDS,

2. Am J Hosp Pharm 46(11): 2286-93 1989

3. Mechatronics: The Science of Intelligent Machines. Mechatronics is
the combination of Mechanical engineering, Electronic engineering, Computer
engineering, Software engineering, Control engineering, and Systems Design
engineering in order to design, and manufacture useful products

        For additional information, please contact:

        Claudia Flaim, Marketing Coordinator
        Phone (Canada): +1.289.470.1456
        Phone (Europe): +39.0471.200.372

        Jojo Kishimoto, International Manager
        3-13-7, Higashi-Kojiya, Ohta-Ku, Tokyo 144-0333, Japan
        Japan: +81.337.451.384

SOURCE Health Robotics

Source: PR Newswire